EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients (UPDATED)
Portfolio Pulse from Vandana Singh
Nexalin Technology announced a study showing its implantable device improves cognitive function in Alzheimer's patients. The study highlights the effectiveness of their Deep Intracranial Frequency Stimulation (DIFS) in enhancing brain function. Despite positive findings, NXL stock is down 4.37% in premarket trading.
October 28, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology's study on their DIFS device shows it improves cognitive function in Alzheimer's patients. Despite positive results, NXL stock is down 4.37% in premarket trading.
The study's positive results could lead to increased interest and potential future revenue for Nexalin Technology. However, the immediate stock price drop suggests market skepticism or other external factors affecting the stock. The long-term impact could be positive if the device gains traction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100